<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4CB92F40-4E51-4027-B354-8C9737DBBCAD"><gtr:id>4CB92F40-4E51-4027-B354-8C9737DBBCAD</gtr:id><gtr:name>University of Tromsoe</gtr:name><gtr:address><gtr:line1>Arctic University of Norway</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Norway</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9FE0E616-6A75-4DCC-BA07-3ADF018A9669"><gtr:id>9FE0E616-6A75-4DCC-BA07-3ADF018A9669</gtr:id><gtr:name>National Cancer Research Institute</gtr:name><gtr:address><gtr:line1>National Cancer Research Institute</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78444E5F-3140-4FEC-B398-D62B796742E8"><gtr:id>78444E5F-3140-4FEC-B398-D62B796742E8</gtr:id><gtr:name>CTRad</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7B48C398-5C6C-4AFB-AC91-370627836FD8"><gtr:id>7B48C398-5C6C-4AFB-AC91-370627836FD8</gtr:id><gtr:name>Sentinel Oncology</gtr:name><gtr:address><gtr:line1>23 Cambridge Science Park</gtr:line1><gtr:line2>Milton Road</gtr:line2><gtr:postCode>CB4 0EY</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>College of Medical, Veterinary &amp;Life Sci</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4CB92F40-4E51-4027-B354-8C9737DBBCAD"><gtr:id>4CB92F40-4E51-4027-B354-8C9737DBBCAD</gtr:id><gtr:name>University of Tromsoe</gtr:name><gtr:address><gtr:line1>Arctic University of Norway</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Norway</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9FE0E616-6A75-4DCC-BA07-3ADF018A9669"><gtr:id>9FE0E616-6A75-4DCC-BA07-3ADF018A9669</gtr:id><gtr:name>National Cancer Research Institute</gtr:name><gtr:address><gtr:line1>National Cancer Research Institute</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78444E5F-3140-4FEC-B398-D62B796742E8"><gtr:id>78444E5F-3140-4FEC-B398-D62B796742E8</gtr:id><gtr:name>CTRad</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7B48C398-5C6C-4AFB-AC91-370627836FD8"><gtr:id>7B48C398-5C6C-4AFB-AC91-370627836FD8</gtr:id><gtr:name>Sentinel Oncology</gtr:name><gtr:address><gtr:line1>23 Cambridge Science Park</gtr:line1><gtr:line2>Milton Road</gtr:line2><gtr:postCode>CB4 0EY</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B668F5DB-0327-4612-BB24-3A74EB1B4CC9"><gtr:id>B668F5DB-0327-4612-BB24-3A74EB1B4CC9</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:surname>Chalmers</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0802755"><gtr:id>8D53738C-76D9-4DA3-8FEA-EFE5EF0B8677</gtr:id><gtr:title>Overcoming treatment resistance in glioblastoma multiforme by tumour specific inhibition of DNA repair.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0802755</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Aims
To identify and characterise novel, effective therapies for treating glioblastoma multiforme (GBM) by tumour-specific inhibition of DNA repair.
Objectives
(1) Demonstrate whether inhibitors of DNA repair proteins increase radiosensitivity of human glioma stem cells. (2) In vivo analysis of the effects of PARP inhibitors on DNA repair in GBM and normal tissues, alone and in combination with radiation and/or chemotherapy. Identification of biomarkers predictive of response to PARP inhibitors. (3) Establish whether tumour-specific downregulation of O6-methylguanine methyltransferase (MGMT) by modulation of PI3kinase/mTOR signalling overcomes temozolomide resistance of human glioma cells with unmethylated MGMT gene promoters.
Design and methodology
(1) Analysis of effects of inhibitors of PARP, DNA-PKcs, ATM, Chk1 and Chk2 on radiation responses of human glioma stem cells, measured by clonogenic survival, induction and repair of DNA damage (immunofluorescence and comet assays) and cell cycle parameters. Active agents will be tested in vivo by quantifying effects on tumorigenicity of irradiated glioma stem cells implanted into the forebrains of SCID mice. 
(2) Immunohistochemical analysis of induction and repair of DNA double strand breaks, measured by H2AX, 53BP1 and Rad51 foci, in tumour specimens and hair follicles of patients in early phase clinical trials of the PARP inhibitor AZD2281 +/- radiotherapy and/or temozolomide. Dual staining will address cell cycle phase specificity. Repair parameters will be correlated with progression-free and overall survival.
(3) Measurement of effects of inhibitors of p38MAPkinase, mTOR or ERK signalling on MGMT gene and protein expression and temozolomide sensitivity of human glioma cells and glioma stem cells.
Scientific opportunities
Studies on glioma stem cells will verify or refute previous observations that they are radioresistant, and elucidate mechanisms underlying this phenotype. Translational studies using tumour resection specimens will interrogate in vivo effects of PARP inhibitors on DNA repair processes in GBM and normal tissues treated with radiotherapy and chemotherapy. Understanding the mechanisms underlying effects of PI3kinase/mTOR inhibition on MGMT expression will provide novel insights into interactions between oncogenic signalling pathways and protein translation, and elucidate the key factors regulating activity of this DNA repair protein. 
Medical opportunities
All aspects of this proposal are aimed at improving treatment of GBM. Overcoming radioresistance of glioma stem cells is likely to be necessary to achieve tumour cure; elucidating mechanisms of sensitisation by PARP inhibitors in vivo and identifying predictive biomarkers will define their therapeutic role; and tumour-specific downregulation of MGMT may improve outcomes in GBM that are resistant to existing therapies.</gtr:technicalSummary><gtr:fund><gtr:end>2015-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2757231</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Research Institute (NCRI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NCRI Brain Tumour CSG</gtr:department><gtr:description>UK glioblastoma radiotherapy-drug combinations consortium</gtr:description><gtr:id>A0548878-D3C5-49E6-8D37-834F20A9FA7C</gtr:id><gtr:impact>Workshop taking place in Glasgow on 16-17 March 2017</gtr:impact><gtr:outcomeId>58c042b603f895.86049021-2</gtr:outcomeId><gtr:partnerContribution>CTRad supporting workshop expenses and travel for invited speakers.
NCRI Brain Tumour CSG supporting workshop administration.
Clinical Trials Unit Glasgow supporting workshop administration and future development of the clinical trial.</gtr:partnerContribution><gtr:piContribution>Based on my previous scientific and clinical research in this field I initiated and am organising and hosting a workshop aimed at developing a multi-centre, multi-arm, multi-stage clinical trial of radiotherapy in combination with various DNA repair inhibitors in the treatment of glioblastoma. The consortium will include clinicians, biological and imaging scientists, pharmaceutical companies, statisticians and consumer representatives.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sentinel Oncology</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Hypoxia-activated PARP inhibitors</gtr:description><gtr:id>8C81DACD-2187-44FE-98F4-1F98647528A5</gtr:id><gtr:impact>Medical Research Council Fellowship Industry Partnership Award</gtr:impact><gtr:outcomeId>nRsiwQmFCAE-1</gtr:outcomeId><gtr:partnerContribution>Jointly developed research concept, assisted in writing of grant application, provided funding 'in kind' as detailed in application.</gtr:partnerContribution><gtr:piContribution>Initiated collaboration, jointly developed research concept, wrote grant application to Medical Research Council Fellowship Industry Partnership Award, secured funding and appointed research associate.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>CTRad</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK glioblastoma radiotherapy-drug combinations consortium</gtr:description><gtr:id>5708916A-0C33-4006-B0C5-4CA86EC61AB9</gtr:id><gtr:impact>Workshop taking place in Glasgow on 16-17 March 2017</gtr:impact><gtr:outcomeId>58c042b603f895.86049021-1</gtr:outcomeId><gtr:partnerContribution>CTRad supporting workshop expenses and travel for invited speakers.
NCRI Brain Tumour CSG supporting workshop administration.
Clinical Trials Unit Glasgow supporting workshop administration and future development of the clinical trial.</gtr:partnerContribution><gtr:piContribution>Based on my previous scientific and clinical research in this field I initiated and am organising and hosting a workshop aimed at developing a multi-centre, multi-arm, multi-stage clinical trial of radiotherapy in combination with various DNA repair inhibitors in the treatment of glioblastoma. The consortium will include clinicians, biological and imaging scientists, pharmaceutical companies, statisticians and consumer representatives.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PARADIGM</gtr:description><gtr:id>5EDC78DE-E325-4465-8C4D-848B51DDF14F</gtr:id><gtr:impact>PARADIGM study is open and has recruited 3 patients to date.</gtr:impact><gtr:outcomeId>565729e3b63026.35442980-2</gtr:outcomeId><gtr:partnerContribution>Study funded by AstraZeneca and endorsed by CRUK through CTAAC. Assistance with study design and partnership with AstraZeneca provided by the Combinations Alliance.</gtr:partnerContribution><gtr:piContribution>Clinical trial design and delivery.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PARADIGM</gtr:description><gtr:id>CF67F7BE-53C9-464A-A6B1-D01A9DD37ADB</gtr:id><gtr:impact>PARADIGM study is open and has recruited 3 patients to date.</gtr:impact><gtr:outcomeId>565729e3b63026.35442980-1</gtr:outcomeId><gtr:partnerContribution>Study funded by AstraZeneca and endorsed by CRUK through CTAAC. Assistance with study design and partnership with AstraZeneca provided by the Combinations Alliance.</gtr:partnerContribution><gtr:piContribution>Clinical trial design and delivery.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PARADIGM-2</gtr:description><gtr:id>49E312EE-7A35-4942-9777-0135E3727FBC</gtr:id><gtr:impact>Clinical trial protocol complete.</gtr:impact><gtr:outcomeId>56572aaa452285.46459952-2</gtr:outcomeId><gtr:partnerContribution>Funding from AstraZeneca.
Funding and assistance with study design and management of the collaboration with AstraZeneca from CRUK.</gtr:partnerContribution><gtr:piContribution>Clinical trial design and protocol delivery. Translational research design.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Clinical Trials Unit (CTU) Glasgow</gtr:department><gtr:description>UK glioblastoma radiotherapy-drug combinations consortium</gtr:description><gtr:id>B20C544A-63A7-48D5-9964-5F5EE70E920F</gtr:id><gtr:impact>Workshop taking place in Glasgow on 16-17 March 2017</gtr:impact><gtr:outcomeId>58c042b603f895.86049021-3</gtr:outcomeId><gtr:partnerContribution>CTRad supporting workshop expenses and travel for invited speakers.
NCRI Brain Tumour CSG supporting workshop administration.
Clinical Trials Unit Glasgow supporting workshop administration and future development of the clinical trial.</gtr:partnerContribution><gtr:piContribution>Based on my previous scientific and clinical research in this field I initiated and am organising and hosting a workshop aimed at developing a multi-centre, multi-arm, multi-stage clinical trial of radiotherapy in combination with various DNA repair inhibitors in the treatment of glioblastoma. The consortium will include clinicians, biological and imaging scientists, pharmaceutical companies, statisticians and consumer representatives.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PARADIGM-2</gtr:description><gtr:id>8E6BC3F2-E312-4B4F-8487-389E813D6F14</gtr:id><gtr:impact>Clinical trial protocol complete.</gtr:impact><gtr:outcomeId>56572aaa452285.46459952-1</gtr:outcomeId><gtr:partnerContribution>Funding from AstraZeneca.
Funding and assistance with study design and management of the collaboration with AstraZeneca from CRUK.</gtr:partnerContribution><gtr:piContribution>Clinical trial design and protocol delivery. Translational research design.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Tromso</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>Radiation and cancer associated fibroblasts</gtr:description><gtr:id>C69C54D6-FADB-4D44-840A-747716C0B049</gtr:id><gtr:impact>Hellevik T, Pettersen I, Berg V, Winberg JO, Moe BT, Bartnes K, Paulssen RH, Busund LT, Bremnes R, Chalmers A, Martinez-Zubiaurre I. Cancer-associated fibroblasts from human NSCLC survive ablative doses of radiation but their invasive capacity is reduced. Radiat Oncol. 2012; 7(1):59.

Hellevik T, Pettersen I, Berg V, Winberg JO, Moe BT, Bartnes K, Paulssen RH, Busund LT, Bremnes R, Chalmers A, Martinez-Zubiaurre I. Cancer-associated fibroblasts from human NSCLC survive ablative doses of radiation but their invasive capacity is reduced. Radiat Oncol. 2012; 7(1):59.</gtr:impact><gtr:outcomeId>JNApoDAFmEL-1</gtr:outcomeId><gtr:partnerContribution>Intellectual contribution to project concept, conducted experiments, data interpretation, manuscript writing.</gtr:partnerContribution><gtr:piContribution>Intellectual contribution to project concept, experimental design, data interpretation and manuscript writing.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>BNA2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>99904B61-0484-46C0-9B4D-3C3A641BCD3E</gtr:id><gtr:impact>An oral presentation to 100 audience members entitled 'Optimising chemotherapy and radiotherapy responses of brain tumours - a scientific perspective' in a symposium entitled &amp;quot;Brain tumours: A complex, challenging and under-recognised area of neuroscience&amp;quot;.

None to date.</gtr:impact><gtr:outcomeId>NzxPvoA8enc</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Samantha Dickson Brain Tumour Trust</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9179DB85-96B9-45E6-A9B2-94CF32E4BF2F</gtr:id><gtr:impact>40 patients, carers and associated members of the public attended a presentation and subsequent discussion on new treatments for brain tumours, as part of the Samantha Dickson Brain Tumour Trust Patient Information Day in Glasgow.

Patients contacted me for information about clinical trials.</gtr:impact><gtr:outcomeId>DTRk7E71RGg</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited speaker at European Association of Neuro-Oncology conference 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CC3729FE-A61A-4848-A0F8-5DD8C94B1BD2</gtr:id><gtr:impact>Delivered an oral presentation entitled 'Precision radiation oncology' as part of a special session jointly organised by EANO, SNO and ASNO as part of the European Association of Neuro-Oncology biannual conference.</gtr:impact><gtr:outcomeId>58c049570767f6.32336139</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited speaker at British Neuro-Oncology Society 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A967CF0E-2231-4C89-86AC-B2D40B74D315</gtr:id><gtr:impact>Gave an oral presentation entitled 'Targeting glioblastoma stem cells in clinical studies' as part of the Education Day at the British Neuro-Oncology Society, Leeds, 2016</gtr:impact><gtr:outcomeId>58c047bfc7c7e2.75791931</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Brain Tumour Support Group</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9E0CFEEC-AD4A-475E-B37B-A302F1017A1A</gtr:id><gtr:impact>30 patients with brain tumours or relatives attended their monthly support group meeting. I gave an informal talk about my research projects and the clinical trials arising from them.

No measurable impacts.</gtr:impact><gtr:outcomeId>prNk5C9VAFA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Brain Tumour Support Group</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>1E3F73C5-6CA0-472C-9802-E757B47666D7</gtr:id><gtr:impact>Informal presentation on my research and on clinical trials for patients with brain tumours.

None.</gtr:impact><gtr:outcomeId>600F506CC54</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2007,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited speaker at NCRI Cancer Conference 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>33C9D274-9B44-4770-92F1-FCB87721B9C8</gtr:id><gtr:impact>Gave an oral presentation entitled 'Why don't drug companies provide access to drugs for use in combination with radiotherapy?' as part of a radiotherapy symposium at the 2016 NCRI Cancer Conference, and participated in a subsequent Q&amp;amp;A session.</gtr:impact><gtr:outcomeId>58c048a38f6f34.15246883</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CRUK Open Evening</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>67AF41F7-CBEE-4A6F-8545-D18A98AF8678</gtr:id><gtr:impact>120 members of the public attended an open evening, including CUK fundraisers, school children, patients. I gave a 20 minute talk on radiotherapy research.

No specific impacts recorded.</gtr:impact><gtr:outcomeId>rHNN54AqHJD</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The Brain Tumour Charity department visit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2AFF8A10-F18C-4174-99B3-44FE112A305A</gtr:id><gtr:impact>Four members of my laboratory (including myself) presented previous and ongoing research findings to other members of the Institute of Cancer Sciences and the CRUK Beatson Institute and to the Chief Scientific Officer of The Brain Tumour Charity. New collaborations were formed and potential funding opportunities highlighted.</gtr:impact><gtr:outcomeId>58c0458ae6eac1.09289171</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Brain Tumour Research department visit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E6C7B534-DB03-4755-9CF8-606E3157674E</gtr:id><gtr:impact>I organised and hosted a visit from the Chief Scientific Officer of Brain Tumour Research to the department at which short talks were given by local brain tumour researchers and a discussion held about gaps in the UK brain tumour research infrastructure and potential funding solutions.</gtr:impact><gtr:outcomeId>58c04658abd997.38002586</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Third sector organisations</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Brain Tumour UK</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>F6BE8F75-E6C1-4ED0-A8FB-53DB77B3968A</gtr:id><gtr:impact>60 patients, carers, health care professionals and charity workers attended a presentation and discussion as part of the Brain Tumour UK Annual Conference in Glasgow.

Patients and charity workers contacted me for information about clinical trials.</gtr:impact><gtr:outcomeId>Gi7wDfaaPT9</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited speaker at UK Radiation Oncology conference 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>107515AA-6173-49D2-8E6F-F2E18316CD9F</gtr:id><gtr:impact>Gave an oral presentation entitled 'Combining radiotherapy with DNA damage and repair inhibitors' and participated in a Q&amp;amp;A session.</gtr:impact><gtr:outcomeId>58c049d92dbc07.65629075</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ESTRO Pre-Meeting Radiobiology Course 2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F9019A1C-0E5F-43E7-8EDA-152AC565DFCC</gtr:id><gtr:impact>Organised and gave an oral presentation during a one-day workshop entitled 'Clinical applications of new combinations: how to test and optimise novel biological agents in combination with radiotherapy'. Facilitated discussions during the workshop.</gtr:impact><gtr:outcomeId>58c04a782d8bd0.87899736</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Senior Clinical Fellowship</gtr:description><gtr:end>2014-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>F920AFF8-12A2-49BF-99EB-8CEF1B9E1CE2</gtr:id><gtr:outcomeId>52C0B07A2A70</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>368203</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2020-01-02</gtr:end><gtr:fundingOrg>National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)</gtr:fundingOrg><gtr:fundingRef>NC/P001335/1</gtr:fundingRef><gtr:id>C2AC178B-9795-4151-994D-6BF6311696A4</gtr:id><gtr:outcomeId>58c04415265167.54295203</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2017-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>328000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Trial Grant (PARADIGM)</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>AstraZeneca</gtr:fundingOrg><gtr:fundingRef>C16583/A17870</gtr:fundingRef><gtr:id>7F7212B7-89D8-4FC5-9AE2-C46E920873EA</gtr:id><gtr:outcomeId>56dea9fdab5f75.91928245</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>244000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Trial Grant</gtr:description><gtr:end>2020-07-02</gtr:end><gtr:fundingOrg>AstraZeneca</gtr:fundingOrg><gtr:id>6479C829-3B59-46A0-A38C-DFEAF84EC3EF</gtr:id><gtr:outcomeId>56dea6fbdcea92.01880870</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2015-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>225000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Award (CSO)</gtr:description><gtr:end>2017-01-02</gtr:end><gtr:fundingOrg>Chief Scientist Office (CSO)</gtr:fundingOrg><gtr:fundingRef>ETM/405</gtr:fundingRef><gtr:id>B6C27493-78D3-4F6E-8FE5-9ABF2E3A6367</gtr:id><gtr:outcomeId>56dea95b74d025.18307013</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Bayer Healthcare Drug Discovery Project Award</gtr:description><gtr:end>2017-01-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C16583/A19438</gtr:fundingRef><gtr:id>B7812A23-6406-4D76-8764-13EDF28CE040</gtr:id><gtr:outcomeId>56dea85de9a0f9.18330422</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>FRCR exam board member</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DD049174-28BA-4574-9AAC-4CA045806101</gtr:id><gtr:impact>Improved knowledge of radiobiology in the Clinical Oncology workforce</gtr:impact><gtr:outcomeId>kGM7C1E4gj9</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ESTRO-ACROP guideline &amp;quot;target delineation of glioblastomas&amp;quot;</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>ESTRO-ACROP guideline &amp;quot;target delineation of glioblastomas&amp;quot;</gtr:guidelineTitle><gtr:id>7F807FAB-221A-4ABC-A4B6-50DD97BE58E6</gtr:id><gtr:outcomeId>58c04d60ef6a21.88981855</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.sciencedirect.com/science/article/pii/S0167814015006611</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Deputy Chair of the Clinical and Translational Radiotherapy Research Working Group (CTRad)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A4D244CE-1DBB-4729-9825-C0ACFC1B5CA2</gtr:id><gtr:impact>Organised, hosted, participated in and delivered lectures and presentations in regular Academic Think Tanks, Clinical Trials Proposals Guidance meetings, Clinical Trials Workshops, Topic Based Academic Workshops and Academic Workshops for Clinical Oncology Trainees. Together these activities have increased the number and quality of academic and research active Clinical Oncologists in the UK, increased the number of radiotherapy clinical trials, increased the number of patients recruited into clinical trials and helped to deliver improvements in clinical outcomes and quality of life through successful delivery of these trials.</gtr:impact><gtr:outcomeId>56deaf9ceada67.58254141</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://ctrad.ncri.org.uk/about-ctrad/ctrad-achievements-and-vision</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Consensus Statement Drug-Radiotherapy Combinations</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>Consensus Statement: Clinical development of new drug-radiotherapy combinations</gtr:guidelineTitle><gtr:id>90B4C957-E567-4DE9-B5CA-05CAC74E4E17</gtr:id><gtr:outcomeId>58c04ccb6a1596.58346671</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.nature.com/nrclinonc/journal/v13/n10/full/nrclinonc.2016.79.html</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Increased funding for radiotherapy in Scottish Cancer Strategy</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>72328AEC-0BED-43B4-B152-CCD2B5935A8E</gtr:id><gtr:outcomeId>58c04bbc328783.36539384</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type><gtr:url>http://www.gov.scot/Publications/2016/03/9784</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ICR MSc Oncology Module Leader</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>71E3DAD8-350C-4E33-87A9-0615F6AA6833</gtr:id><gtr:impact>Increase in academic clinical oncology personnel in the UK. Increase in radiotherapy clinical trials.</gtr:impact><gtr:outcomeId>iHJtUC6EJGf</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>884AFB98-1037-4047-837D-588B671048D7</gtr:id><gtr:title>Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bfe79c99ed83fb6ea4eaa76b8e94d418"><gtr:id>bfe79c99ed83fb6ea4eaa76b8e94d418</gtr:id><gtr:otherNames>L?ser DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn><gtr:outcomeId>MqGbFLGoxjR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>383938C0-89FB-4DBC-BC3D-D1CDAB745D86</gtr:id><gtr:title>Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma.</gtr:title><gtr:parentPublicationTitle>Nature cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4f600e1b224c4e49eb486713275b41a"><gtr:id>c4f600e1b224c4e49eb486713275b41a</gtr:id><gtr:otherNames>Tardito S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1465-7392</gtr:issn><gtr:outcomeId>5657283b175435.30992345</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1AE1EE75-9B7B-4671-9045-965B14399B70</gtr:id><gtr:title>Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP Inhibitors</gtr:title><gtr:parentPublicationTitle>Anti-Cancer Agents in Medicinal Chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8383b0661be998658ee25ed0bd23bd1"><gtr:id>d8383b0661be998658ee25ed0bd23bd1</gtr:id><gtr:otherNames>J. Chalmers A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>585d4667a43093.00246210</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B83FA04-CC5C-41B3-8166-4836957DB11E</gtr:id><gtr:title>Differential sensitivity of Glioma stem cells to Aurora kinase A inhibitors: implications for stem cell mitosis and centrosome dynamics.</gtr:title><gtr:parentPublicationTitle>Stem cell research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f444f7f1ec18c9153b1d36a8e3404ce8"><gtr:id>f444f7f1ec18c9153b1d36a8e3404ce8</gtr:id><gtr:otherNames>Mannino M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1873-5061</gtr:issn><gtr:outcomeId>544f5e1af053a4.87075882</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>038F7FA3-DD44-4B48-8A32-832E549737F6</gtr:id><gtr:title>Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets.</gtr:title><gtr:parentPublicationTitle>Seminars in radiation oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03c1327946d51b2f20b9df1ab44754ff"><gtr:id>03c1327946d51b2f20b9df1ab44754ff</gtr:id><gtr:otherNames>Chalmers AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1053-4296</gtr:issn><gtr:outcomeId>QWcWQxQssUf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B134DBBE-2EFA-4B12-95A3-F16A82C3B3E8</gtr:id><gtr:title>Changes in the Secretory Profile of NSCLC-Associated Fibroblasts after Ablative Radiotherapy: Potential Impact on Angiogenesis and Tumor Growth.</gtr:title><gtr:parentPublicationTitle>Translational oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aad5a03344fc69cea1fb6a6c99698642"><gtr:id>aad5a03344fc69cea1fb6a6c99698642</gtr:id><gtr:otherNames>Hellevik T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1936-5233</gtr:issn><gtr:outcomeId>pm_13039_29_23418618</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50FC90C5-0994-4147-BBC6-A18AC54E2BAE</gtr:id><gtr:title>Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/389dfa1738032a14b6cf77181edd3a4e"><gtr:id>389dfa1738032a14b6cf77181edd3a4e</gtr:id><gtr:otherNames>Gilbert DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_13039_29_22108516</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB69DA65-E345-42E8-855F-1C7139D366A4</gtr:id><gtr:title>Overcoming resistance of glioblastoma to conventional cytotoxic therapies by the addition of PARP inhibitors.</gtr:title><gtr:parentPublicationTitle>Anti-cancer agents in medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03c1327946d51b2f20b9df1ab44754ff"><gtr:id>03c1327946d51b2f20b9df1ab44754ff</gtr:id><gtr:otherNames>Chalmers AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1871-5206</gtr:issn><gtr:outcomeId>WS19iMVVLb9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DF06C29-B4DE-4DA8-A415-42D792214B12</gtr:id><gtr:title>Cancer-associated fibroblasts from human NSCLC survive ablative doses of radiation but their invasive capacity is reduced.</gtr:title><gtr:parentPublicationTitle>Radiation oncology (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aad5a03344fc69cea1fb6a6c99698642"><gtr:id>aad5a03344fc69cea1fb6a6c99698642</gtr:id><gtr:otherNames>Hellevik T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1748-717X</gtr:issn><gtr:outcomeId>pm_13039_29_22500976</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79AFD357-FCD1-481B-92F4-093C9C429137</gtr:id><gtr:title>Radioresistance of glioma stem cells: intrinsic characteristic or property of the 'microenvironment-stem cell unit'?</gtr:title><gtr:parentPublicationTitle>Molecular oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f444f7f1ec18c9153b1d36a8e3404ce8"><gtr:id>f444f7f1ec18c9153b1d36a8e3404ce8</gtr:id><gtr:otherNames>Mannino M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1574-7891</gtr:issn><gtr:outcomeId>pm_13039_29_21659010</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C58D8DD-F6E7-4044-AD26-307712B8D6AB</gtr:id><gtr:title>Abrogation of radioresistance in glioblastoma stem-like cells by inhibition of ATM kinase.</gtr:title><gtr:parentPublicationTitle>Molecular oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3980221746b77170f0935da657e06db"><gtr:id>e3980221746b77170f0935da657e06db</gtr:id><gtr:otherNames>Carruthers R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1574-7891</gtr:issn><gtr:outcomeId>544f5e1b5e5548.32976965</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2D78B55-B71B-44FD-ACDA-5583716F1455</gtr:id><gtr:title>DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets.</gtr:title><gtr:parentPublicationTitle>Current medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c46d5cd6c1eef5862ac93a7c9c62d4d9"><gtr:id>c46d5cd6c1eef5862ac93a7c9c62d4d9</gtr:id><gtr:otherNames>Alagoz M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0929-8673</gtr:issn><gtr:outcomeId>pm_13039_29_22788763</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BEDCC570-81DC-46DF-A0CF-4CCE1BD23BF4</gtr:id><gtr:title>DNA Repair and Resistance to Topoisomerase I Inhibitors: Mechanisms, Biomarkers and Therapeutic Targets</gtr:title><gtr:parentPublicationTitle>Current Medicinal Chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c46d5cd6c1eef5862ac93a7c9c62d4d9"><gtr:id>c46d5cd6c1eef5862ac93a7c9c62d4d9</gtr:id><gtr:otherNames>Alagoz M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>585d468642e8b5.57415586</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6AC965CE-7D01-44C7-9935-A24D3E623213</gtr:id><gtr:title>Evaluating novel radiation techniques for the treatment of cerebral metastases.</gtr:title><gtr:parentPublicationTitle>The British journal of radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03c1327946d51b2f20b9df1ab44754ff"><gtr:id>03c1327946d51b2f20b9df1ab44754ff</gtr:id><gtr:otherNames>Chalmers AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-1285</gtr:issn><gtr:outcomeId>Vnk398U7kdw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2D6B6D1-6AD8-4806-8C7E-8991DAF035CC</gtr:id><gtr:title>Current and investigational drug strategies for glioblastoma.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/73b1f4a82eafcdd6f8fbc6a9b92a4275"><gtr:id>73b1f4a82eafcdd6f8fbc6a9b92a4275</gtr:id><gtr:otherNames>Ajaz M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>544f5d976e1c48.55854616</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AA92B86-29C6-440E-93D6-309F9DBD3FF3</gtr:id><gtr:title>Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1f3483d7905eee270bc071e04f741660"><gtr:id>1f3483d7905eee270bc071e04f741660</gtr:id><gtr:otherNames>Ichim G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn><gtr:outcomeId>5657283a72c078.35276740</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18587F55-82F0-4375-A124-377CB7B1C047</gtr:id><gtr:title>Selective Inhibition of Parallel DNA Damage Response Pathways Optimizes Radiosensitization of Glioblastoma Stem-like Cells.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f64de194166a31e67cae892cba67b4c8"><gtr:id>f64de194166a31e67cae892cba67b4c8</gtr:id><gtr:otherNames>Ahmed SU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>5657283ac04706.71718517</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A15770E2-AF3A-4BED-A185-60DAD08719C8</gtr:id><gtr:title>mTOR inhibition and levels of the DNA repair protein MGMT in T98G glioblastoma cells.</gtr:title><gtr:parentPublicationTitle>Molecular cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e62839c206644f8ab7da9dca1290f1e"><gtr:id>0e62839c206644f8ab7da9dca1290f1e</gtr:id><gtr:otherNames>Smalley S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1476-4598</gtr:issn><gtr:outcomeId>544f5e1b2d1f64.30942360</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A77BF042-8ED4-40C7-8CE5-72CF83919CA4</gtr:id><gtr:title>Systematic review of supportive care needs in patients with primary malignant brain tumors.</gtr:title><gtr:parentPublicationTitle>Neuro-oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b37a120d236cc7f8b08242cf86cec28d"><gtr:id>b37a120d236cc7f8b08242cf86cec28d</gtr:id><gtr:otherNames>Ford E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1522-8517</gtr:issn><gtr:outcomeId>pm_13039_29_22307475</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83516FFB-85DD-4D97-9246-56CBD03250E2</gtr:id><gtr:title>Complementary use of bioluminescence imaging and contrast-enhanced micro-computed tomography in an orthotopic brain tumor model.</gtr:title><gtr:parentPublicationTitle>Molecular imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc04edac5dbedbf0e3b1c2071e3094c4"><gtr:id>bc04edac5dbedbf0e3b1c2071e3094c4</gtr:id><gtr:otherNames>Yahyanejad S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1535-3508</gtr:issn><gtr:outcomeId>5657283a97fd08.19300972</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C818786-3222-4910-A1F8-18AC1C1D1B38</gtr:id><gtr:title>A UK-wide survey of follow-up practices for patients with high-grade glioma treated with radical intent.</gtr:title><gtr:parentPublicationTitle>Journal of evaluation in clinical practice</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d8de0dabfad45e7f89d13d28fae9a65"><gtr:id>7d8de0dabfad45e7f89d13d28fae9a65</gtr:id><gtr:otherNames>Catt SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1356-1294</gtr:issn><gtr:outcomeId>pm_13039_29_21143347</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>403172E2-B7DF-4D07-A407-56964E74929D</gtr:id><gtr:title>Synthesis and Evaluation of a Radioiodinated Tracer with Specificity for Poly(ADP-ribose) Polymerase-1 (PARP-1) in Vivo.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d9553c0630a6b203441b2c89ab6229a"><gtr:id>8d9553c0630a6b203441b2c89ab6229a</gtr:id><gtr:otherNames>Zmuda F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>5657283ae41b45.41531870</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0802755</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>006DC612-6329-4D37-A540-5FB2CA634720</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.5  Radiotherapy</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>